Compare · AURA vs GILD
AURA vs GILD
Side-by-side comparison of Aura Biosciences Inc. (AURA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AURA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $185.89B, about 241.3x AURA ($770.5M).
- Over the past year, AURA is up 18.0% and GILD is up 33.0% - GILD leads by 15.0 points.
- AURA has been more active in the news (15 items in the past 4 weeks vs 10 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 11 for AURA).
- Company
- Aura Biosciences Inc.
- Gilead Sciences Inc.
- Price
- $7.43+3.34%
- $149.90+2.43%
- Market cap
- $770.5M
- $185.89B
- 1M return
- +5.69%
- +14.24%
- 1Y return
- +18.02%
- +32.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 15
- 10
- Recent ratings
- 11
- 25
Aura Biosciences Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest AURA
- Chief People Officer Person Julie was granted 107,611 shares (SEC Form 4)
- Chief Reg. & Quality Officer Kratz Erica was granted 100,885 shares (SEC Form 4)
- Chief Medical Officer Hopkins Janet Jill was granted 58,850 shares, increasing direct ownership by 18% to 380,190 units (SEC Form 4)
- SVP, Finance & PAO Elazzouzi Amy was granted 23,540 shares, increasing direct ownership by 20% to 143,600 units (SEC Form 4)
- Chief Operating Officer Abu-Absi Susan was granted 134,513 shares (SEC Form 4)
- SEC Form S-8 filed by Aura Biosciences Inc.
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form EFFECT filed by Aura Biosciences Inc.
- SEC Form 3 filed by new insider Person Julie
- SEC Form 3 filed by new insider Kratz Erica
Latest GILD
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)